A judicial investigation has pinpointed the exact moment a technical failure contaminated fentanyl produced by HLB Pharma. Despite knowing about the issue, both technicians and company owners reportedly decided to continue production of the drug. This decision allegedly led to a tragic outcome, though details of the specific incident are not provided in this text. The findings suggest a severe case of negligence, as the firm prioritized production over patient safety. The information indicates a conscious decision was made to proceed despite the known risk of contaminated product reaching consumers. Legal repercussions for HLB Pharma and those responsible are anticipated following this discovery. The case raises serious questions about quality control within the pharmaceutical industry.